Predictors of sustained response to alpha interferon therapy in chronic hepatitis C

Clinical Biochemistry

Volumn 32, Issue 7, 1999, Pages 537-545

  Neuman, Manuela G ^a   Benhamou, Jean Pierre ^b   Martinot, Michelle ^b   Boyer, Nathalie ^b   Shear, Neil H ^a   Malkiewicz, Izabella ^a   Katz, Gady G ^a   Suneja, Ashima ^a   Singh, Steve ^a   Marcellin, Patrick ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b BEAUJON HOSPITAL   (France)

Author keywords

Chronic hepatitis C; Cystokines; IFN therapy; Transforming growth factor beta; Tumor necrosis factor alpha

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ALCOHOL LIVER DISEASE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FIBRIN FORMATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; LIVER INJURY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AGED; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER; MALE; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 0033433974     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(99)00053-3     Document Type: Conference Paper

References (60)

1. Sherlock S. Antiviral therapy for chronic hepatitis C viral infection. J Hepatol. 23:(Suppl 2):1995;3-7.
2. Fried M.W., Hoofnagle J.H. Therapy of hepatitis C. Semin Liver Dis. 15:1995;82-91.
3. Marcellin P.B. Treatment of chronic viral hepatitis. Clin Gastroenterol. 8:1994;233-253.
4. Marcellin P., Martinot M., Boyer N., Castelnau C., Benhamou J.P., Erlinger S. Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives. Gastroenterol Clin Biol. 19:1995;991-1000.
5. EASL International Consensus Conference on Hepatitis C (Paris 26-28 February 1999) Consensus Statement. J Hepatol 1999; 30: 956-61.
6. Christian M.D., Sachez R.L., Soloway R.D. Injection site vasculitis in patient receiving interferon alpha for chronic hepatitis C. J Am Acad Dermatol. 37:1997;118-120.
7. Coroneos E., Truong L., Olivero J. Fibrillary glomerulonephritis associated with hepatitis C viral infection. Am J Kidney Dis. 29:1997;132-135.
8. Czaja A.J. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis. 15:1997;125-144.
9. Falaschi P., D'Urso R., Proietti A., Martocchia A., Pastore R., Angelucci L. Effect of r-interferon alpha administration on hypothalamus-pituitary-thyroid axis in chronic hepatitis. Life Sci. 60:1997;43-50.
10. Hadziyannis S.K. Diabetes mellitus and chronic hepatitis C virus infection. Hepatol. 29:1999;604-605.
11. Hadziyannis S.J. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat. 4:1997;9-28.
12. Henrion J.M., Colin L., Schapira M., Delannoy A., Heller F.R. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure a case-controlled, hemodynamic study of 17 consecutive cases . Hepatology. 29:1999;427-433.
13. Cooreman M.P., Stadhouders P. Optimal antiviral therapy of chronic hepatitis caused by hepatitis C virus. Orv Hetil. 138:(Suppl 1):1997;1476-1482.
14. Di Bisceglie A.M., Hoofnagle J.H., Krawczynski K. Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology. 105:1993;858-862.
15. Di Marco V., Lo Iacono O., Camma C., et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J Med Virol. 51:1997;17-24.
16. Dusheiko G.M., Zuckerman A.J. Treatment of chronic viral hepatitis C. J Antimicrob Chemother. 32:(Suppl A):1993;107-120.
17. Fargion S., Fracanzani A.L., Sampietro M., et al. Liver iron influences response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol. 9:1997;497-503.
18. Ferenci P. Historical treatment of chronic hepatitis B and chronic hepatitis C. Gut. 34:(Suppl 2):1993;S69-S73.
19. Imai Y., Kawata S., Tamura S., et al. Recombinant interferon-alpha-2a for treatment of chronic hepatitis C results of a multicenter randomized controlled dose study . Liver. 17:1997;88-92.
20. Piresi M., Fabris C., Toniutto P., et al. Endogenous interferon-alpha concentration and outcome of interferon treatment inpatients with chronic hepatitis C. Dig Dis Sci. 42:1997;767-771.
21. Bonis P.A., Cappelleri J.C., Kaplan M.M., Lau J. Correlation of biochemical response to interferon alpha with histological improvement in hepatitis C A meta-analysis of diagnostic test characteristics . Hepatology. 26:1997;1035-1044.
22. Camma C., Giunta M., Linea C., Pagliaro L. The effect of interferon on the liver in chronic hepatitis C a quantitative evaluation of histology by meta-analysis . J Hepatol. 26:1997;1187-1199.
23. Schalm SW. Antiviral therapy of hepatitis C. Scand J Gastroenterol 1997; Suppl 223: 46-9.
24. Simpson K.J., Lukacs N.W., Coletti L., Strieter R.M., Kunkel S.L. Cytokines in the liver. J Hepatol. 27:1997;1120-1132.
25. Neuman M.G. Cytokines and Inflamed Liver. Clin Invest Med. 23:1998;1-6.
26. Neuman M.G., Shear N.H., Bellentani S., Tiribelli C. Role of cytokines in ethanol-induced hepatocytotoxicity in Hep G2 cells. Gastroenterology. 114:1998;157-169.
27. Zhang Z.X., Milich D.R., Peterson D.L., et al. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis. 175:1997;1294-1301.
28. Iacovacci S.M., Barca S., Sargiacomo M., et al. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocyets infected in vitro. Hepatology. 26:1997;1328-1337.
29. Imada K.F., Koyama Y., Nakano I., Yamada M., Katano Y., Hayakawa T. Naive and memory T cell infiltrates in chronic hepatitis C phenotypic changes with interferon treatment . Clin Exp Immunol. 109:1997;59-66.
30. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection pre- and posttreatment with interferon alfa . Hepatology. 24:1996;6-9.
31. Itoh Y. Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon. Dig Dis Sci. 40:1995;2423-2430.
32. Carreno V., Parra A., Navas S., Quiroga J.A. Granulocyte-macrophage colony-stimulating factor as adjuvant therapy for factor as adjuvant therapy for interferon alpha treatment of chronic hepatitis C. Cytokine. 8:1996;318-322.
33. Carrerno V. Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection. J Viral Hepatol. 4:(Suppl 2):1997;83-86.
34. Kakumu S.O., Ishikawa T., Iwata K., Yano M., Yoshioka K. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 108:1997;138-143.
35. Kishihara Y., Hayashi J., Yoshimura E., Yamaji K., Nakashima K., Kashiwagi S. IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci. 41:1996;315-321.
36. Kishihara Y. IL-1 beta an dTNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci. 41:1996;315-321.
37. Kuzushita N. High levels of serum interlukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol. 32:1997;169-174.
38. Quiroga J.A. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig Dis Sci. 39:1994;2485-2496.
39. Lohr H.F. Liver-infiltrating and circulating CD4+ T cells in chronic hepatitis C immunodominant epitopes, HLA-restriction and functional significance . Liver. 16:1996;174-182.
40. Hino K., Sainokaimi S., Shimoda K., et al. Genotypes and titers of hepatitis C virus for predicting response to interferon therapy in patients with chronic hepatitis C. J Med Virol. 42:1994;229-305.
41. Ruiz-Arguelles G.J. Laboratory measurement of human cytokines. JIFCC. 7:1995;12-15.
42. Malaguarnera M., DiFazio I., Romeo M.A., Restuccia S., Laurino A., Trovato B.A. Elevation of IL6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol. 32:1997;211-215.
43. Neuman MG, Benhamou JP, Shear NH, et al. Interleukine 6 normalization during interferon-ribavirin combination therapy in chronic hepatitis C. J Hepatol 1999c; 30(Suppl 1) (PC06/49): 242.
44. Martin J. Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine. 8:1996;313-317.
45. Quiroga JA. Induction of interlekin-12 production in chronic hepatis C virus infection correlates with the hepatocellular damage. J Infect Dis 19998; 178: 247-51.
46. Neuman MG, Benhamou JP, Shear NH, et al. Serum tumor necrosis factor as a predictor of sustain response to alpha-interferon-ribavirin combination therapy in chronic hepatitis C. J Hepatol 1999; 30(Suppl 1) (PC06/109): 257.
47. Zylberberg H.R., Pol S., Masson A., et al. Soluble tumor necrosis factors in chronic hepatitis C a correlation with histological fibrosis and activity . J Hepatol. 30:1999;185-191.
48. Khoruts A., Stanke L., McClain C.F., Logan G., Allen J.I. Circulating tumor necrosis factor, interleukin-1 and interleukin 6 concentrations in chronic alcoholic patients. Hepatology. 13:1991;267-276.
49. Sheron N., Bird G., Goka J., Alexander G., Wiliiams I.L. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol. 84:1991;453-499.
50. Bedossa P., Poynard T., Mathurin P., Lemaigre G., Chaput J.C. Transforming growth factor beta 1 in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon . Gut. 34:1993;S147-S148.
51. Roulot D., Durand H., Coste T., Rautureau J., Strosberg A.D., Benarous R., Marullo S. Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C absence of correlation between high levels and severity of disease . Hepatology. 21:1995;298-304.
52. Kishihara Y., Hayashi J., Yoshimura E., Yamaji K., Nakashima K., Kashiwagi S. IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci. 41:1996;315-321.
53. Fabris C., Soardo G., Falleti E., et al. Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res. 18:1998;705-709.
54. Fukuda R., Ishimura N., Ishihara S., et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver. 16:1996;330-339.
55. Larrea E., Garcia N., Qian C., Civeira M.P., Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology. 23:1996;210-217.
56. Malaguarnera M., De Fazio I., Laurino A., Ferlito L., Romano M., Trovato B.A. Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Int J Clin Pharmacol Ther. 35:1997;385-388.
57. Shapiro S., Gershtein V., Elias N., Zuckerman E., Salman N., Lahat N. mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients effects of interferon-alpha (IFN-alpha) treatment . Clin Exp Immunol. 114:1998;55-60.
58. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 339:1998;1493-1499.
59. Kobayashi K., Ishii M., Igarashi T., et al. Profiles of cytokines produced by CD4-positive T lymphocytes stimulated by anti-CD3 antibody in patients with chronic hepatitis C. J Gastroenterol. 33:1998;500-507.
60. Tsushima H., Kawata S., Tamura S., et al. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy association with regression of hepatic fibrosis . J Hepatol. 30:1999;1-7.